Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review
Medical Oncology · 2026
DOI: 10.1007/s12032-026-03393-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2026. Verfasst von Wahyu Widowati und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Maranatha Christian University, Bandung, West Java, 40164, Indonesia. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Killer Cells, Natural, Liver Neoplasms, Immunotherapy, Adoptive. Die Arbeit nennt 105 Literaturangaben.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains a significant global health threat characterized by aggressive progression and high mortality rates. Despite therapeutic advancements, survival for advanced stages is unacceptably low, necessitating innovative approaches like Natural Killer (NK) cell-based immunotherapy. NK cells are crucial innate immune components providing rapid tumor cytotoxicity without prior sensitization. However, the HCC tumor microenvironment (TME) presents a formidable barrier, inducing NK cell dysfunction through immunosuppressive cytokines like TGF-[Formula: see text], chronic hypoxia, and metabolic exhaustion driven by lipid accumulation. This literature review consolidates and integrates findings regarding current NK cell-based strategies in HCC, with particular emphasis on mechanisms of NK cell dysfunction within the TME and therapeutic approaches designed to restore their antitumor activity. Emerging therapeutic strategies involve cytokine-supported approaches, including the adoptive transfer of autologous or allogeneic NK cells expanded ex vivo using stimuli such as IL-15 and IL-21. In parallel, advances in genetic engineering have enabled the development of modified NK cells, including chimeric antigen receptor (CAR)-NK platforms targeting HCC-associated antigens such as glypican-3 (GPC3) and CD147 and bispecific and trispecific killer cell engagers (BiKEs and TriKEs). This review underscores the translational potential of NK cell-based therapies by highlighting unresolved knowledge gaps in the complex interplay between NK cells and the TME. These developments provide a foundation for optimizing NK cell immunotherapy and improving prognostic outcomes for patients with HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Maranatha Christian University, Bandung, West Java, 40164, Indonesia.
- Master Program of Skin Ageing and Aesthetic Medicine, Faculty of Medicine, Maranatha Christian University, Bandung, West Java, 40164, Indonesia.
- Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
- Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Jakarta, 10430, Indonesia.
- Biomedical Engineering, Department of Electrical Engineering, Faculty of Engineering, Universitas Indonesia, Depok, West Java, 16424, Indonesia.
- Biomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung, West Java, 40163, Indonesia.
ORCID-Profile: Massoud Vosough
Zitieren
APA
Widowati, W., Wargasetia, T. L., Sadri, B., Nainggolan, I. M., Azis, R., Rifana, S. D., Rismani, E., & Vosough, M. (2026). Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review. Medical Oncology. https://doi.org/10.1007/s12032-026-03393-5
Vancouver
Widowati W, Wargasetia TL, Sadri B, Nainggolan IM, Azis R, Rifana SD, et al. Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review. Medical Oncology. 2026. doi:10.1007/s12032-026-03393-5
BibTeX
@article{Widowati2026,
author = {Widowati, Wahyu and Wargasetia, Teresa Liliana and Sadri, Bahareh and Nainggolan, Ita Margaretha and Azis, Rizal and Rifana, Safira Dinda and Rismani, Elham and Vosough, Massoud},
title = {Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review},
journal = {Medical Oncology},
year = {2026},
doi = {10.1007/s12032-026-03393-5}
}
EUVIMED